PharmaMar SA (PharmaMar)

Oncology Corporate Profile

HQ Location

Avda. De los Reyes, 1
Pol. Ind. La Mina-Norte, 28770-Colmenar Viejo Madrid, Sp

Company Description

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and commercializing marine-based drugs to treat cancer. Yondelis¥Ô is Spain's first anti-tumor drug. Yondelis is currently approved for STS in 34 countries outside the EEA, and in 10 of those countries for platinum sensitive ROC as well (including Brazil and Canada). Yondelis is approved for STS and platinum sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Yondelis¥Ô is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has five other compounds in clinical development: Aplidin¥Ô, Irvalec¥Ô, Zalypsis¥Ô, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program.

Website: http://www.pharmamar.com/

Brand Generic Indication
YONDELIS«• trabectedinYONDELIS«• (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PM01183marine derived antitumoral agent Breast cancerIII
PM01183marine derived antitumoral agent Ovarian cancerIII
Aplidin_ / plitidepsinmarine derived antitumoral agent 2nd line metastatic Multiple MyelomaIII
Yondelis_ / trabectedinmarine derived antitumoral agent 2nd line metastatic Ovarian cancerIIIJanssen
PM01183marine derived antitumoral agent LeukemiaII
PM01183marine derived antitumoral agent Pancreatic cancerII
Yondelis_ / trabectedinmarine derived antitumoral agent Breast cancerIIJanssen
Yondelis_ / trabectedinmarine derived antitumoral agent Pediatric cancerIIJanssen
PMO1183 (+ Doxorubicin)marine derived antitumoral agent Small Cell Lung Cancer (SCLC)I
PM01183marine derived antitumoral agent Various cancer typesI
PM060184marine derived antitumoral agent Various cancer typesI
Irvalec_synthetic depsipeptideVarious cancer typesI
Aplidin_ / plitidepsinmarine derived antitumoral agent 2nd line metastatic Non-Hodgkin's Lymphoma (NHL)II

View additional information on product candidates here »

Pipeline image

Source


http://www.pharmamar.com/

Recent News Headlines

There are no news items to display